Clinical Trials
321 trialsAn Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer
Boehringer Ingelheim
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
GlaxoSmithKline
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
M.D. Anderson Cancer Center
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
Hoffmann-La Roche
Phase I Comparative Bioavailability Study
AstraZeneca
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
A Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Hong Kong), Ltd.
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
M.D. Anderson Cancer Center
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC
ORIC Pharmaceuticals
MK-7339-007
Merck Sharp & Dohme LLC
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
NIVALIS
West China Hospital
VASTUS
Idience Co., Ltd.
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
Genmab
A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors
Nanolattix Biotechnology Co., Ltd.
A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors
Incyte Corporation
A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
REST
Children's National Research Institute
aCCeleR8-001
Shionogi Inc.
Phase Ia/Ib Study of RS-0139 in Patients With a Recurrent, Locally Advanced or Metastatic Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
KEYNOTE-603
ModernaTX, Inc.
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Genentech, Inc.
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
GK01IIT-TZ03
Tianjin Medical University Cancer Institute and Hospital
A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 Inhibitor
Boehringer Ingelheim
Screening Study for Participants With Malignant Tumors
Hoffmann-La Roche
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
Xinqiao Hospital of Chongqing
GUARDIAN-02
Tianjin Medical University Cancer Institute and Hospital
DPTX3186 in Wnt Pathway Activated Solid Tumors
Dewpoint Therapeutics
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shanghai Shengdi Pharmaceutical Co., Ltd
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation